Prashanth Ashok Kumar
Overview
Explore the profile of Prashanth Ashok Kumar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
108
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ashok Kumar P, Sampat P, Sandhu M, Suresh Kumar V, Smith A, Paulraj S, et al.
Breast Cancer Res Treat
. 2025 Jan;
PMID: 39827229
Background: Cryotherapy with taxane infusion is a noninvasive strategy for preventing peripheral neuropathy (PN), but the efficacy of this approach has not been proven. Methods: A systematic search was conducted,...
2.
Patkar S, Chen A, Basnet A, Bixby A, Rajendran R, Chernet R, et al.
NPJ Precis Oncol
. 2025 Jan;
9(1):6.
PMID: 39789067
No abstract available.
3.
Patkar S, Chen A, Basnet A, Bixby A, Rajendran R, Chernet R, et al.
NPJ Precis Oncol
. 2024 Dec;
8(1):280.
PMID: 39702609
Immune checkpoint inhibitors (ICI) have become integral to treatment of non-small cell lung cancer (NSCLC). However, reliable biomarkers predictive of immunotherapy efficacy are limited. Here, we introduce HistoTME, a novel...
4.
5.
Ashok Kumar P, Basnet A, Graziano S
J Cell Immunol
. 2024 Jul;
6(2):82-86.
PMID: 38957649
No abstract available.
6.
Phuna Z, Ashok Kumar P, Haroun E, Dutta D, Lim S
Life Sci
. 2024 Apr;
347:122676.
PMID: 38688384
Antibody-drug conjugates (ADCs) are immunoconjugates that combine the specificity of monoclonal antibodies with a cytotoxic agent. The most appealing aspects of ADCs include their potential additive or synergistic effects of...
7.
Ashok Kumar P, Wang D, Huang D, Sivapiragasam A
JCO Precis Oncol
. 2024 Apr;
8:e2300390.
PMID: 38564683
Purpose: Results from the TAILORx trial revealed that the use of adjuvant chemotherapy along with endocrine therapy had no survival advantage in patients with estrogen receptor (ER)-positive, human epidermal growth...
8.
Paulraj S, Ashok Kumar P, Byrnes S, Ojha N, Singh A, Raj V
Cureus
. 2024 Feb;
16(1):e52717.
PMID: 38384630
Background Appropriate Use Criteria (AUC) for echocardiography are a useful tool to deliver quality healthcare. Our quality-based interventional study was designed to assess the trends in appropriate utilization rates for...
9.
Ashok Kumar P, Ghimire K, Haroun E, Kassab J, Saba L, Gentile T, et al.
Eur J Haematol
. 2023 Oct;
112(3):328-338.
PMID: 37899652
Allogeneic hematopoietic stem cell transplant (allo-HSCT) is increasingly being used in the United States (US) and across the world as a curative therapeutic option for patients with certain high-risk hematologic...
10.
Ashok Kumar P, Basnet A
Transl Lung Cancer Res
. 2023 Oct;
12(9):1838-1841.
PMID: 37854158
No abstract available.